These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1060 related items for PubMed ID: 17884451

  • 1. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
    Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X.
    Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
    [Abstract] [Full Text] [Related]

  • 3. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, Doerries C, Horváth T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U.
    Circulation; 2007 Jul 10; 116(2):163-73. PubMed ID: 17592079
    [Abstract] [Full Text] [Related]

  • 4. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
    Kiyici S, Ersoy C, Kaderli A, Fazlioglu M, Budak F, Duran C, Gul OO, Sigirli D, Baran I, Tuncel E, Erturk E, Imamoglu S.
    Diabetes Res Clin Pract; 2009 Oct 10; 86(1):44-50. PubMed ID: 19674806
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
    Sidhu JS, Cowan D, Tooze JA, Kaski JC.
    Am Heart J; 2004 Jun 10; 147(6):e25. PubMed ID: 15199366
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH.
    Basic Res Cardiol; 2010 May 10; 105(3):399-407. PubMed ID: 19902320
    [Abstract] [Full Text] [Related]

  • 7. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
    Shargorodsky M, Michaelova K, Boaz M, Gavish D, Zimlichman R.
    Diabet Med; 2007 Nov 10; 24(11):1254-60. PubMed ID: 17725634
    [Abstract] [Full Text] [Related]

  • 8. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus.
    Harashima K, Hayashi J, Miwa T, Tsunoda T.
    Metabolism; 2009 Jun 10; 58(6):739-45. PubMed ID: 19446110
    [Abstract] [Full Text] [Related]

  • 9. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC.
    Clin Endocrinol (Oxf); 2007 Feb 10; 66(2):282-9. PubMed ID: 17224000
    [Abstract] [Full Text] [Related]

  • 10. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
    Sidhu JS, Cowan D, Kaski JC.
    Am J Cardiol; 2004 Jul 15; 94(2):151-6. PubMed ID: 15246889
    [Abstract] [Full Text] [Related]

  • 11. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May 15; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 12. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 May 15; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 13. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS.
    Diabetes Metab Res Rev; 2003 May 15; 19(6):487-93. PubMed ID: 14648808
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA.
    Am Heart J; 2007 Mar 15; 153(3):445.e1-6. PubMed ID: 17307426
    [Abstract] [Full Text] [Related]

  • 15. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC.
    Nephrol Dial Transplant; 2006 Sep 15; 21(9):2399-405. PubMed ID: 16720596
    [Abstract] [Full Text] [Related]

  • 16. Pulse wave velocity and coronary risk stratification.
    Mendonça MI, Reis RP, Sousa AC, Gomes S, Faria P, Pereira A, Silva B, Serrão M, Santos N, Sousa FS, Silva JA, Sousa J, Ornelas I, Freitas S, Cardoso A, Araújo JJ.
    Rev Port Cardiol; 2009 Feb 15; 28(2):155-71. PubMed ID: 19438151
    [Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F, Caglayan E, Hsueh WA.
    Endocrinol Metab Clin North Am; 2006 Sep 15; 35(3):561-74, ix. PubMed ID: 16959586
    [Abstract] [Full Text] [Related]

  • 18. Diabetes mellitus and renal failure: effects on large artery stiffness.
    Aoun S, Blacher J, Safar ME, Mourad JJ.
    J Hum Hypertens; 2001 Oct 15; 15(10):693-700. PubMed ID: 11607799
    [Abstract] [Full Text] [Related]

  • 19. Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.
    Park SE, Kang ES, Kim DH, Kim SK, Lee JH, Ahn CW, Lee HC, Cha BS.
    Diabet Med; 2009 Jun 15; 26(6):577-81. PubMed ID: 19538231
    [Abstract] [Full Text] [Related]

  • 20. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thulé PM, Sutliff RL, Hart CM.
    Vascul Pharmacol; 2007 Jun 15; 46(6):456-62. PubMed ID: 17337254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.